Latest news with #IPF
Business Wire
3 days ago
- Business
- Business Wire
UBS Invests in UK Fintech Icon Solutions to Shape the Future of Payments Technology
LONDON--(BUSINESS WIRE)-- Icon Solutions, the UK fintech enabling banks globally to design and implement state-of-the-art payment systems, has today announced a new equity investment from UBS. Icon has also secured additional funding from existing investors Citi and NatWest. Pieter Brouwer, Head of Group Operations and Technology Office (GOTO) for Personal & Corporate Banking and GWM Switzerland & International, at UBS comments: 'Icon, an important partner of UBS, plays a crucial role in modernizing payment platforms with innovative infrastructure solutions.' Brouwer adds: 'This investment reinforces our partnership with Icon and confirms our commitment to deliver faster to market, future-ready payment solutions for our clients. The collaboration helps us drive innovation at scale and enhances our capabilities for seamless instant payments and advanced transaction processing.' UBS will join existing investors Citi and NatWest – who are using the Icon Payments Framework (IPF) to accelerate their respective payments modernization programs and deliver more value for customers – in shaping the strategic direction and ongoing development of IPF. Tom Kelleher, Co-Founder and Director of Icon Solutions, comments: 'This investment round is further endorsement of our founding belief that banks should be empowered to lead their own payments transformation. With IPF now internationally proven and increasingly adopted by major financial institutions, we look forward to continuing our close partnerships with Citi, NatWest and UBS to build on this global momentum and deliver truly innovative and ground-breaking payments solutions.' IPF is a payment development framework that gives banks the technology and processes to independently accelerate the transformation of their own payment infrastructure, allowing them to build, test and deploy payment processing solutions much faster, while staying in total control of timelines and costs. Learn more about IPF. About Icon Solutions Icon Solutions is a fintech company that has been designing and implementing state-of-the-art payments systems since 2009. Our core product – the Icon Payments Framework (IPF) – is an internationally proven payments development framework that is trusted by Tier 1 banks across the globe such as Citi, NatWest, UBS and BNP Paribas. IPF gives banks the technology and processes to independently accelerate the transformation of their payments infrastructure, allowing them to build, test and deploy payments processing solutions much faster, while staying in total control of timelines and costs. For more information, visit About UBS UBS is a leading and truly global wealth manager and the leading universal bank in Switzerland. It also provides diversified asset management solutions and focused investment banking capabilities. UBS manages 6.1 trillion dollars of invested assets as per fourth quarter 2024. UBS helps clients achieve their financial goals through personalized advice, solutions and products. Headquartered in Zurich, Switzerland, the firm is operating in more than 50 markets around the globe. UBS Group shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE). For more information, visit UBS
Hindustan Times
11-06-2025
- Health
- Hindustan Times
Doctors should not refuse treatment under IPF scheme
PUNE: Towards effective implementation of the Indigent Patients Fund (IPF) scheme and putting an end to discrimination against needy patients, the state government has directed the Maharashtra Medical Council (MMC) to instruct doctors in charitable hospitals not to deny treatment or examination to patients from economically weaker sections, officials said. A government resolution (GR) was issued on Tuesday granting permission to establish a Special Inspection Team under the charity commissioner, medical education and drugs department; and Charitable Hospital Helpdesk for implementation of the IPF scheme. The team will include the charity commissioner, Maharashtra or a nominated member; principal secretary, medical education and drugs department or a nominated member; and head of the Charitable Hospital Helpdesk or a nominated member. Furthermore, the GR states that all charitable hospitals must implement various health schemes of the central and state governments. The departments must prepare and submit to the law and judiciary department a list of hospitals that have received land or concessions from local municipal corporations or central/state government/district collector's office. The decision was taken during a meeting headed by chief minister Devendra Fadnavis on April 23, 2025, to review the functioning of the Charitable Hospital Helpdesk, officials said. For effective implementation of the IPF scheme, the charity commissioner's office must ensure that charitable hospitals display the status of vacant beds, government health schemes, and other related information. This updated information must also be available online and on a dashboard. Besides, disciplinary action should be taken under the Maharashtra Public Trusts Act, 1950 and directions issued by the Bombay High Court (HC) against charitable hospitals that avoid implementing the scheme or do not use the online system developed for the scheme. Rameshwar Naik, head of the Special Help Cell, Maharashtra, said that the decision has been taken by the chief minister with the aim that no needy patient should be deprived of treatment for financial reasons. 'An inspection committee will be constituted to conduct an audit of charitable hospitals. The government has also approved 186 posts of charitable health workers that will be filled through outsourcing. These posts will be filled on priority and will assist eligible patients to avail the treatment,' he said. Meanwhile, the government said that to determine the economic status of patients, beneficiary patients must submit any of the following documents namely income certificate from tehsildar, ration card/BPL card or PAN card (if available). The revenue and forests department must instruct tehsildars to verify and issue income certificates after thorough checks. All charitable hospitals should operate only one IPF account. If multiple IPF accounts exist, the funds should be consolidated into one. A centralised system should be created for monitoring these funds through the charity commissioner's office. The facility There are 58 charitable hospitals in Pune, 74 in Mumbai, and 430 across the rest of the state. The IPF scheme was framed by the Bombay HC and rolled out in September 2006; all charitable hospitals in the state have to allocate two per cent of their gross billing to help indigent patients. All charitable hospitals have the mandate to earmark and reserve 10% of their beds for indigent patients to be treated for free, and 10% of beds for economically weaker sections. This aid has to be in the form of free treatment to those with an annual income below ₹1.8 lakh, and at 50% discounted billing for patients with an annual income below ₹3.60 lakh.
Indian Express
09-06-2025
- Politics
- Indian Express
Bengaluru stampede: ‘Action against police looks like scapegoating,' Indian Police Foundation tells Karnataka CM Siddaramaiah
The Indian Police Foundation (IPF) – a group representing retired police personnel – has asked the Karnataka government to reinstate the police officers who have been suspended in the wake of the Bengaluru stampede. Eleven people died after a stampede occurred outside the M Chinnaswamy Stadium in the Karnataka capital during the victory celebrations of the Royal Challengers Bengaluru (RCB) in this year's Indian Premier League (IPL). In a letter addressed to Karnataka Chief Minister Siddaramaiah on Monday, the IPF stated, 'The suspension of five police officers, including the Commissioner of Police, prior to the completion of a detailed investigation, has raised serious concerns within the professional policing community across the country. Actions taken without establishing individual responsibility would be seen as scapegoating rather than principled accountability and may have a demoralising effect on the entire police force, while undermining institutional integrity.' 'In the spirit of constructive engagement, the Indian Police Foundation offers to support the Government by conducting a Post-Incident Review and Analysis. This would be a non-adversarial, independent exercise, not intended for fault-finding, but focused on identifying systemic gaps, good practices, and actionable lessons to guide police operations and training. The IPF has in its membership a distinguished team of former DGPs, former civil servants, senior police leaders, forensic scientists, public safety experts, and academics who can undertake this exercise with neutrality, sensitivity, and professionalism,' the letter added. A day after the Bengaluru stampede, the state government had suspended Bengaluru Commissioner of Police B Dayananda, Additional Commissioner of Police (West) Vikash Kumar Vikash, Deputy Commissioner of Police (Central) Shekhar H Tekkannavar, ACP (Cubbon Park sub-division) C Balakrishna, and police inspector Girish A K on Thursday. Besides the Opposition, social media users have also flooded the government with requests to reinstate Dayananda.
National Post
09-06-2025
- Health
- National Post
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
Article content MONTREAL — Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic. Article content Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future. Article content 'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.' Article content Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases. Article content 'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.' Article content About Innospera Pharma Article content Article content Article content
Business Wire
09-06-2025
- Business
- Business Wire
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
MONTREAL--(BUSINESS WIRE)-- Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006 Share Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future. 'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.' Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases. 'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.' About Innospera Pharma Innospera is a Montreal-based biotechnology company developing first-in-class GPR84 and GPR40 modulators to restore homeostasis in diseases driven by metabolic and inflammatory dysfunction. The company's lead compound, ING-006, is a synthetic lipid designed to address Idiopathic Pulmonary Fibrosis (IPF) by resolving inflammation and reducing fibrogenesis. Innospera is backed by a strong syndicate of investors including Investissement Québec, Seido Capital, and Anges Québec. For more information, visit
